No abstract

No abstract

molecule ligand (e.g., or a monoclonal antibody (e.g., J591) that has affinity for PSMA. Treatment is generally well-tolerated, but adverse events have been reported. We aimed to assess patient reported outcomes in prospective clinical trials.Methods: From 2017 to 2021, 79 receiving either 177Lu-PSMA-617 or 225Ac-J591 with complete FACT-P and BPI instruments at baseline and 12 weeks later. We used linear mixed model analyses with no imputation for missing data among participants with evaluable data to examine whether PROs changed over time and whether change in PROs was associated with treatment received, baseline clinical factors, and response to treatment (i.e., best change in PSA after baseline).Results: 91% receiving 177Lu-PSMA-617 and 100% receiving 225Ac-J591 experienced at least one adverse event, such as pain, fatigue, dry mouth, nausea, and hematologic toxicity. No overall change over time was observed in quality of life or pain (Ps > .05), and treatment (i.e., 177Lu-PSMA-617 vs. 225Ac-J591) was not associated with change in PROs (Ps > .05). Baseline factors (e.g., ECOG performance status, metastases) were not associated with change over time in PROs (Ps > .05). Response to treatment was associated with change over time in pain intensity, functional well-being, prostatespecific quality of life, and overall quality of life.Conclusions: This is the first study we are aware of to compare change in PROs among patients receiving different TRT therapies. PROs did not change over time overall or as a function of PSMA-TRT received; however, change in clinically important PROs was associated with response to treatment. Future studies should replicate and extend these findings to examine change in PROs as a potential prognostic factor for response to PSMA-TRT.

No abstract

Sažetak Uvod: Hidrocefalus je hidrodinamički poremećaj toka cerebrospinalnog likvora gdje dolazi do proširenja komornog sistema i povećanja pristiska na mozak. Tretman je uglavnom hirurški. Ciljevi: Utvrditi zastupljenost pojedinih tipova hidrocefalusa po toku i uzroku, analizirati dobnu i polnu zastupljenost, te diskutovati najvažnije nalaze. Materijal i metode: Riječ je o retropektivnoj studiji nastaloj na osnovu analize podataka o hirurškom liječenju pacijenata od hidrocefalusa u Službi za neurohirurgiju Univerzitetskog kliničkog centra Republike Srpske u 2017 i 2018 godini. Rezultati i diskusija: U našem uzorku nešto je veća zastupljenost hroničnih formi hidrocefalusa (53.8% vs 46.2%). U najvišem procentu se radilo o obstruktivnom hidrocefalusu (84%), dok je učestalost kongentialnog hidrocefalusa zabilježena u 2 % slučajeva. Zaključak: Hidrocefalus uglavnom zahtjeva hirurški tretman, te je uvijek prije svake odluke neophodna korelacija svih dostupnih podataka i parametara kao i dalji adekvatan nadzor od strane neurohirurga.